Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective
treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The
primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in
these patients.